Home>Topics>Stocks>Biomarin Pharmaceutical

Biomarin Pharmaceutical BMRN

  1. All
  2. Commentary
  3. Headlines
    1. With An Iffy Non-Oncology Pipeline, Roche Pays Up For InterMune

      Headlines

      Tue, 26 Aug 2014

      remained a frequent flier whenever an analyst or writer has wanted to write up a story on potential biotech/pharma M&A - Roche has been tied to Alexion (NASDAQ: ALXN ), BioMarin (NASDAQ: BMRN ), and Chugai on the more Complete Story »

    2. A Young Power Couple's Kickstart Portfolio

      Headlines

      Fri, 6 Jun 2014

      184 0.07 N/A Matt's Roth IRA: Alpine Dynamic Dividend AOD 1,134 0.42 Matt's Roth IRA: Biomarin Pharmaceuticals BMRN 185 0.07 Matt's Roth IRA: Corcept Therapeutics CORT 108 0.04 N/A Matt's Roth IRA: Cyberonics CYBX $179 0.07 N

    3. Slightly Lowering BioMarin's Fair Value After Peg-Pal Delay, but Stock Remains Undervalued

      Commentary

      Fri, 2 May 2014

      Pal because of the redesign of its Phase III trial, and we've also pushed back the launches of other late stage candidates BMRN -673 and BMN-701, as we have factored delayed starts and longer enrollment periods into our analysis. Given the heavy investment

    4. Our Outlook for Health-Care Stocks

      Headlines

      Fri, 28 Jun 2013

      attractiveness, collaborative fit, and digestible size. Our top biotech picks are Onyx ONXX, Regeneron REGN, Incyte INCY, Biomarin BMRN , and Seattle Genetics SGEN. Valeant VRX made the biggest acquisition splash over the past few months, acquiring Bausch & Lomb

    5. Raising Our BioMarin Fair Value Estimate Based on Positive Long-Term Outlook

      Commentary

      Mon, 6 May 2013

      We're raising our fair value estimate for BioMarin BMRN to $71 per share from $59, after reassessing our long-term growth assumptions for the firm. Specifically, we have boosted

    6. From Barron’s, April 29, 2013 (Part 2)

      Commentary

      Sat, 27 Apr 2013

      premium as the related biotech research has finally become more productive and fruitful. Mentioned are PFE, BMY, LLY, BIIB, BMRN . http://online.barrons.com/article/SB50001424052748703889404578438831955549290.html?mod=BOL_twm_col

    7. BioMarin's 1Q Fundamentals Are Strong; Late-Stage Pipeline Supports Positive Moat Trend

      Commentary

      Thu, 25 Apr 2013

      BioMarin BMRN reported first-quarter results that were in line with our expectations, and we're maintaining our $59 per share fair value

    8. Our Outlook for Health-Care Stocks

      Headlines

      Fri, 29 Mar 2013

      attractiveness, collaborative fit, and digestible size. Our top biotech picks are Onyx ONXX, Regeneron REGN, Incyte INCY, Biomarin BMRN , and Seattle Genetics SGEN. Top Health-Care Sector Picks Star Rating Fair Value Estimate Economic Moat Fair Value Uncertainty

    9. Increasing BioMarin's FV on Expanding and Advancing Pipeline, Long-Term Tax Implications

      Commentary

      Fri, 22 Feb 2013

      BioMarin's BMRN fourth-quarter 2012 results were in line with our expectations, and the firm's 2013 guidance on sales and earnings was lower

    10. Raising Our Fair Value Estimate on BioMarin's Positive GALNS Data

      Commentary

      Tue, 6 Nov 2012

      BioMarin BMRN has announced positive Phase III data for key pipeline candidate GALNS, and we're raising our fair value estimate by $3 (a

    « Prev12345Next »
    Content Partners